Federal law would ban pharmacy abortion pills, limit access to medical offices only
S. 3697 — SAVE Moms and Babies Act of 2026 · Filed by Cindy Hyde-Smith (R-MS) · 37 cosponsors · Introduced Jan 27, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal drug law to prohibit the FDA from approving new abortion medications and from granting investigational exemptions for abortion drugs. For mifepristone (the one abortion drug currently approved), it imposes strict new requirements: limiting use to in-person administration in medical offices only, requiring prescribers to have surgical backup capabilities, banning pharmacy dispensing, and mandating detailed adverse-event reporting. Existing investigational uses have 3 years to wind down or be rescinded.
Why we flagged it
The bill's operative mechanism is a direct restriction on FDA approval authority and a set of regulatory burdens (REMS requirements, prescriber certification, dispensing limits) applied to mifepristone. These restrictions reduce practical access to a currently approved medication.
What the text implies
- The 3-year wind-down for existing investigational uses may effectively end ongoing clinical research into abortion medications, reducing the evidence base for future policy decisions.
- Prescriber certification requirements (surgical intervention capability, ectopic pregnancy diagnosis, blood transfusion access) may eliminate most primary-care and telehealth providers, concentrating access in hospital-based settings.
- Adverse-event reporting requirements, while framed as safety measures, create a detailed federal registry of abortion drug use that could be used for enforcement or prosecution under state laws.
- The definition of 'abortion drug' is extremely broad ('any drug intended to kill the unborn child') and could capture drugs used for miscarriage management or ectopic pregnancy treatment if interpreted expansively.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill restricts women's access to a currently legal medication by narrowing where and how it can be obtained, requiring in-person medical office visits only and eliminating pharmacy dispensing. It also imposes new prescriber qualifications that may reduce the number of providers willing or able to offer the drug, effectively reducing practical access even where legal.
Named in the bill
FDA (Food and Drug Administration), mifepristone (Mifeprex), Section 505 of Federal Food, Drug, and Cosmetic Act, Section 503(b)(1) (prescription drug classification), Section 505-1 (REMS requirements)
Where it stands
37 cosponsors: 37 Republicans.
- Jan 27, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jan 27, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions.”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $420,000 in lobbying spend. A filing names 51 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Cindy Hyde-Smith, the sponsor, reported $1,329,320 in PAC receipts in the 2026 cycle.
- Susan B Anthony List — $420,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (6,048 characters) on Sep 23, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 14,707 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-09-23.
“Federal law would ban pharmacy abortion pills, limit access to medical offices only” QuorumCivic. https://share.quorumcivic.app/bill/119/s3697 Report an error